The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer
Open accessAbstract
BACKGROUND: The authors sought to improve the toxicity of conventional concurrent chemoradiation therapy for stage III nonsmall cell lung cancer (NSCLC) by using proton‐beam therapy to escalate the radiation dose to the tumor. They report early results of a phase 2 study of high‐dose proton therapy and concurrent chemotherapy in terms of toxicity, failure patterns, and survival. METHODS: Forty‐four patients with stage III NSCLC were treated with 74 grays (radiobiologic equivalent) proton therapy with weekly carboplatin (area under the curve, 2 U) and paclitaxel (50 mg/m 2). Disease was staged with positron emission tomography/computed tomography (CT), and treatments were simulated with 4‐dimensional (4D) CT to account for tumor motion. Protons were delivered as passively scattered beams, and treatment simulation was repeated during the treatment process to determine the need for adaptive replanning. RESULTS: Median follow‐up time was 19.7 months (range, 6.1‐44.4 months), and median overall survival time was 29.4 months. No patient experienced grade 4 or 5 proton‐related adverse events. The most common nonhematologic grade 3 toxicities were dermatitis (n = 5), esophagitis (n = 5), and pneumonitis (n = 1). Nine (20.5%) patients experienced local disease recurrence, but only 4 (9.1%) had isolated local failure. Four (9.1%) patients had regional lymph node recurrence, but only 1 (2.3%) had isolated regional recurrence. Nineteen (43.2%) patients developed distant metastasis. The overall survival and progression‐free survival rates were 86% and 63% at 1 year. CONCLUSIONS: Concurrent high‐dose proton therapy and chemotherapy are well tolerated, and the median survival time of 29.4 months is encouraging for unresectable stage III NSCLC. Cancer 2011;. © 2011 American Cancer Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Cited by
Proton therapy – Present and future
Mohan, R., & Grosshans, D. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.006 · Cited by 608
Self-citationChang, J. Y., Liu, Y., Zhu, Z., Welsh, J. W., Gomez, D. R., Komaki, R., Roth, J. A., & Swisher, S. G. (2013) · Cancer · doi:10.1002/cncr.28217 · Cited by 91
“Diagnosis interval (range), mo 1 (0-6) 33 (7-210)”
Metadata
- Authors
- Chang, J. Y., Komaki, R., Lu, C., Wen, H. Y., Allen, P. K., Tsao, A., Gillin, M., Mohan, R., & Cox, J. D.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-03-22
- Volume
- 117
- Issue
- 20
- Pages
- 4707-4713
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1966418691
- Cited by
- 180
- References
- 1
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. https://app.cochat.ai/papers/10.1002/cncr.26080
- The paper
- Chang, J. Y., Komaki, R., Lu, C., Wen, H. Y., Allen, P. K., Tsao, A., Gillin, M., Mohan, R., & Cox, J. D. (2011). Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. https://doi.org/10.1002/cncr.26080
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.